1. Pink Sheet
  2. >>Market Access

Now It’s Asthma Inhalers’ Turn: Boehringer Will Cap Copays, Cut Some List Prices As Pressure Grows

 
• By Cathy Kelly

Inhalers seem poised to take insulin’s spot as a top punching bag for Rx industry critics. BI’s action, a first among the marketers of inhalers for asthma and COPD, follows challenges from Bernie Sanders and the FTC on the cost of such products.

Inhalers Succeeding Insulins As Target Of Pricing Complaints • Source: Shutterstock

Copays for all Boehringer Ingelheim GmbH inhaler products will be capped at $35 per fill for patients who are commercially insured, underinsured or uninsured beginning June 1 under a new program announced by the company on 7 March.

Key Takeaways

  • Copays for all of Boehringer’s inhalers will be limited to $35 for commercial insurance members and the uninsured starting I June.

  • The company will also lower the list prices of Spiriva HandiHaler and Atrovent beginning 1 January 2025.

  • Sen

Like other manufacturer-funded copay support programs, it will not be available to enrollees in government sponsored insurance programs like

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

HHS Secretary Kennedy Says Trump Will Make Final Decision On Mifepristone Policy

 
• By Derrick Gingery

With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.